Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GSK Woes Raise Big Pharma R&D Question

Dec 04 2017

• By Melanie Senior

Related Content

Putting The Pieces Together Again: GSK Creates End-To-End Business Units

Jan 01 2011

J&J’s Approach To Sourcing Innovation: Closing The Networking Gap

Oct 15 2014

GlaxoSmithKline R&D Under Scrutiny In Bid For Fresh Funding

Oct 17 2011

GSK Says R&D Productivity Up, But Story Is About Culture, Not Numbers

Feb 20 2012

Biopharma R&D Productivity And Growth 2017: Big Pharma Closes The Gap

Dec 13 2017

Walmsley Shakes Up GSK; Cuts More Than 30 Drug Development Programs

Jul 26 2017

R&D Productivity at GSK? He CEDD, She CEDD

Jan 01 2004

GSK CEO Andrew Witty Under Fire About China During Q2 Call

Jul 24 2013

GSK Bags Barron As R&D Boss As Vallance Joins UK Government

Nov 08 2017

GSK Tries to Mimic Real-World Biotech

Feb 01 2009

Related Companies

GSK plc

Eli Lilly and Company

Novartis AG

Pfizer Inc.

BI IO Canada Inc.

Bayer AG

Synlogic, Inc.

Roche Holding AG

Johnson & Johnson

Additional Topics

Business Strategies Innovation BioPharmaceutical

More from Business Strategy

More from In Vivo

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window